Home » Stocks » GenMark Diagnostics

GenMark Diagnostics, Inc. (GNMK)

Stock Price: $15.95 USD 0.41 (2.64%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $16.50 +0.55 (3.45%) Aug 13, 6:08 PM

Stock Price Chart

Key Info

Market Cap 1.13B
Revenue (ttm) 126.94M
Net Income (ttm) -33.65M
Shares Out 71.07M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $15.95
Previous Close $15.54
Change ($) 0.41
Change (%) 2.64%
Day's Open 15.65
Day's Range 15.62 - 16.36
Day's Volume 824,738
52-Week Range 3.36 - 20.88

More Stats

Market Cap 1.13B
Enterprise Value 1.08B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 71.07M
Float 66.78M
EPS (basic) -0.56
EPS (diluted) -0.55
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.50M
Short Ratio 3.32
Short % of Float 9.52%
Beta 3.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.93
PB Ratio 12.19
Revenue 126.94M
Operating Income -26.69M
Net Income -33.65M
Free Cash Flow -22.25M
Net Cash 57.17M
Net Cash / Share 0.80
Gross Margin 22.53%
Operating Margin -21.03%
Profit Margin -26.50%
FCF Margin -17.53%
ROA -10.28%
ROE -64.13%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(34.17% upside)
Current: $15.95
Target: 21.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth24.4%34.73%6.59%25.03%28.82%11.64%33.88%308.64%95.36%-
Gross Profit28.6019.4820.0129.5724.0917.4711.838.83-1.20-1.42
Operating Income-41.81-47.77-59.52-48.98-41.54-39.05-34.88-21.89-23.86-20.03
Net Income-47.35-50.50-61.85-50.60-42.20-38.26-33.64-22.10-23.97-18.40
Shares Outstanding57.6055.6751.1744.1042.1641.3535.2526.2216.579.80
Earnings Per Share-0.82-0.91-1.21-1.15-1.00-0.93-0.95-0.84-1.45-1.88
Operating Cash Flow-34.93-32.51-53.42-35.64-31.92-29.57-23.80-16.24-19.21-18.86
Capital Expenditures-2.09-2.58-4.82-7.00-3.76-5.73-4.27-3.48-1.38-1.86
Free Cash Flow-37.02-35.09-58.24-42.64-35.67-35.30-28.07-19.72-20.59-20.72
Cash & Equivalents54.2245.9372.7542.3246.2271.2610652.5930.3218.33
Total Debt76.7836.0428.0319.829.52-0.040.701.58-
Net Cash / Debt-22.579.8844.7222.5136.7171.2610651.8928.7418.33
Book Value12.1633.5571.1638.1548.6078.0210956.4530.6321.07
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GenMark Diagnostics, Inc.
Country United States
Employees 437
CEO Scott Mendel

Stock Information

Ticker Symbol GNMK
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: GNMK
IPO Date May 28, 2010


GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.